These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9892598)

  • 1. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
    Reed GL; Houng AK
    Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
    Butte AN; Houng AK; Jang IK; Reed GL
    Circulation; 1997 Apr; 95(7):1886-91. PubMed ID: 9107177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
    Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
    Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.
    Mosesson MW; Siebenlist KR; Hernandez I; Lee KN; Christiansen VJ; McKee PA
    J Thromb Haemost; 2008 Sep; 6(9):1565-70. PubMed ID: 18564219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
    Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
    Koncz Z; Bagoly Z; Haramura G; Mezei ZA; Muszbek L
    Thromb Res; 2012 Sep; 130(3):528-34. PubMed ID: 22704462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
    Jansen JW; Haverkate F; Koopman J; Nieuwenhuis HK; Kluft C; Boschman TA
    Thromb Haemost; 1987 Apr; 57(2):171-5. PubMed ID: 2440124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
    Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel method to quantify fibrin-fibrin and fibrin-α
    Morrow GB; Flannery S; Charles PD; Heilig R; Feller T; McQuilten Z; Wake E; Ariens RAS; Winearls J; Mutch NJ; Fischer R; Laffan MA; Curry N
    J Thromb Haemost; 2024 Jun; 22(6):1758-1771. PubMed ID: 38462220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 16. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
    Lee KN; Jackson KW; McKee PA
    Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging.
    Robinson BR; Houng AK; Reed GL
    Circulation; 2000 Sep; 102(10):1151-7. PubMed ID: 10973845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
    Sakata Y; Aoki N
    J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism.
    Martinez MR; Cuker A; Mills AM; Crichlow A; Lightfoot RT; Chernysh IN; Nagaswami C; Weisel JW; Ischiropoulos H
    Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(5):L397-404. PubMed ID: 24414255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.